When Will Retatrutide Be Available?

Retatrutide is not available outside of clinical trials. It has not been approved by the FDA or any regulatory agency. Based on Lilly's stated filing plan and the status of the TRIUMPH Phase 3 program, the most likely scenario is FDA approval in late 2027 or the first half of 2028, with commercial availability beginning in 2028.

On July 23, 2026, alongside the TRIUMPH-2 and TRIUMPH-3 results, Lilly said it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027. That supersedes the earlier "submit in 2026" guidance from its Q4 2025 earnings call (February 4, 2026), and pushes every downstream date out by roughly two quarters. The company has begun "at-risk" manufacturing at facilities in Concord, NC and Limerick, Ireland.

Timeline at a Glance

Milestone	Expected Date	Status
TRIUMPH-4 results	December 2025	Completed — 28.7% weight loss at 12 mg
TRIUMPH-1 results (core pivotal)	May 21, 2026	Completed — 28.3% weight loss at 12 mg (80 wks)
TRIUMPH-2 results	July 23, 2026	Completed — 20.8% weight loss at 12 mg; A1C down up to 1.6%
TRIUMPH-3 results	July 23, 2026	Completed — 22.6% weight loss at 12 mg
BLA submission to FDA	Q1 2027	Stated by Lilly on July 23, 2026
FDA accepts filing	~Q2 2027	Projected (~60 days after submission)
FDA approval decision	Late 2027 – H1 2028	Projected
Commercial launch	2028	Projected

The TRIUMPH Phase 3 Program

Eli Lilly's TRIUMPH program spans nine numbered Phase 3 trials (roughly 8,600 participants between them), plus the separate TRIUMPH-Outcomes cardiovascular and kidney outcomes trial, which accounts for about 10,000 more. Trial focus and status below are per each study's ClinicalTrials.gov record.

Trial	Focus	Status	Expected Completion
TRIUMPH-1	Obesity (core pivotal, 2,339 randomized, 80 weeks)	Completed	Read out May 2026
TRIUMPH-2	Type 2 diabetes with obesity/overweight (nested OSA protocol)	Completed	Read out July 23, 2026
TRIUMPH-3	Obesity with cardiovascular disease	Completed	Read out July 23, 2026
TRIUMPH-4	Knee osteoarthritis	Completed (Dec 2025)	Done
TRIUMPH-5	Head-to-head vs tirzepatide	Active, not recruiting	Primary completion Dec 2026; results to follow in 2027
TRIUMPH-6	Maintenance of weight reduction	Active, not recruiting	Primary completion Apr 2028
TRIUMPH-7	Obesity/overweight with chronic low back pain	Recruiting	Primary completion Sep 2027
TRIUMPH-8	Obesity/overweight	Active, not recruiting	Primary completion Jul 2027
TRIUMPH-9	Obesity/overweight without type 2 diabetes	Active, not recruiting	Primary completion Oct 2028
TRIUMPH-Outcomes	Cardiovascular + kidney outcomes (CVOT)	Active, not recruiting	Primary completion Feb 2029

Why TRIUMPH-1 Is the Most Important

TRIUMPH-1 is the pivotal registration trial with 2,339 randomized participants and an 80-week treatment duration — longer than TRIUMPH-4's 68 weeks. It reported on May 21, 2026: 28.3% average weight loss at 12 mg over 80 weeks, and 30.3% at 104 weeks in a pre-specified extension. This is the trial the weight-management filing rests on.

TRIUMPH-3 Status

TRIUMPH-3 studies weight management in adults with severe obesity and established cardiovascular disease. Lilly reported topline results on July 23, 2026: 22.6% average weight loss at 12 mg and 21.6% at 9 mg over 80 weeks, versus 3.2% on placebo. The ClinicalTrials.gov registry results record had not yet been posted. It is not the event-driven cardiovascular outcomes trial; that is the separate TRIUMPH-Outcomes study. Full detail: TRIUMPH-3 results.

FDA Review Process

Standard Review (Most Likely): 10 Months

Because three GLP-1 obesity medications are already FDA-approved (Wegovy, Zepbound, Saxenda), retatrutide will likely receive a standard 10-month review rather than priority review. The FDA's National Priority Voucher program (used for orforglipron) is unlikely to apply to retatrutide.

Potential Delays

Dysesthesia advisory committee: The dysesthesia side effect (20.9% at 12 mg) could prompt an FDA advisory committee hearing, adding 1-2 months
Manufacturing inspections: FDA facility inspections at Lilly's production sites could flag issues
Complete Response Letter: The FDA could request additional data before granting approval

Three Scenarios

Scenario	BLA Filing	FDA Decision	Launch
Optimistic (priority review)	Q1 2027	Late 2027	H1 2028
Base case (standard review)	Q1 2027	H1 2028	Mid to late 2028
Conservative (filing slips or CRL)	H2 2027 or later	Late 2028 – 2029	2029

How to Access Retatrutide Today

The only legal way to receive retatrutide is through Eli Lilly's clinical trials:

ClinicalTrials.gov — Search all registered retatrutide trials
Lilly Trial Guide — Lilly's trial finder with eligibility screening

Typical Eligibility Criteria

BMI ≥ 30 kg/m², or BMI ≥ 27 with at least one weight-related comorbidity
Age 18+
No GLP-1 receptor agonist use in the prior 90 days
No history of pancreatitis, bariatric surgery, or medullary thyroid carcinoma

See Retatrutide Clinical Trials for detailed information about the TRIUMPH program and Cost & How to Get It for other access options.

Grey Market Is Not a Safe Alternative

Grey market retatrutide sold online by research chemical vendors is unregulated, untested, and not legal for human consumption. Studies show 30% of tested research peptides contained incorrect amino acid sequences and 65% exceeded endotoxin safety thresholds. See Grey Market Retatrutide: Risks and Dangers for the full safety data.

What Happens After Approval

Even after FDA approval, broad availability takes time:

Phase	Timeline Post-Approval	What Happens
Controlled launch	Month 1	Available at specialty obesity centers
Gradual expansion	Months 2–3	Broader distribution to pharmacies
Broad availability	Months 4–6	Widely available if manufacturing is on track
Insurance coverage	Months 3–12	Commercial insurance 3–6 months; Medicare may not cover obesity drugs

Expected Pricing

Based on Lilly's current pricing for Zepbound (~$1,060/month) and retatrutide's superior efficacy profile, analysts project retatrutide will be priced at approximately $1,200–$1,500 per month. Final pricing will be announced closer to launch.

International Availability

Region	Status	Estimated Timeline
United States (FDA)	Core TRIUMPH readouts complete; BLA planned for Q1 2027	Late 2027 – H1 2028
European Union (EMA)	Lilly opened scientific advice with CHMP in late 2024	~2028–2029
United Kingdom (MHRA)	150-day accelerated pathway available	Shortly after US approval
Canada	Parallel review programs available	Submission expected after the US filing
Other markets	Dependent on local regulatory processes	2029+

Frequently Asked Questions

Is retatrutide available now?

No. Retatrutide is only available through clinical trials. It has not been approved by the FDA or any other regulatory agency.

When will retatrutide be FDA approved?

Based on Lilly's stated filing plan, the most likely approval window is late 2027 to the first half of 2028. Lilly said on July 23, 2026 that it plans to submit its BLA in Q1 2027; the FDA then takes about 60 days to accept the filing, followed by a standard 10-month (or priority 6-month) review.

Can my doctor prescribe retatrutide?

Not yet. Once approved, retatrutide will be available by prescription. Until then, the only option is enrollment in a clinical trial.

Will insurance cover retatrutide?

Too early to know. Insurance coverage typically takes 3-12 months after FDA approval. Commercial insurance tends to be faster than Medicare. Lilly will likely offer a savings program similar to the Zepbound Savings Card.

What should I do while waiting?

Talk to your doctor about currently approved options: semaglutide (Wegovy) or tirzepatide (Zepbound) for obesity, or check eligibility for retatrutide clinical trials at ClinicalTrials.gov.

Sources

Eli Lilly. (2026). Q4 2025 Earnings Call, February 4, 2026. Investor Relations.
Eli Lilly. (2026). "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials," July 23, 2026. Press release.
Eli Lilly. (2025). TRIUMPH-4 results. Press release.
ClinicalTrials.gov. TRIUMPH trials: NCT05931367, NCT05934019, NCT05913128.
NextGen GLP-1. (2026). Retatrutide FDA Approval Status: February 2026 Update. Link.

Questions to ask your doctor

Is an approved GLP-1 medication a reasonable option for me?
How can I access a legitimate, prescribed option safely?
What are the specific risks of unregulated or compounded sources?
What monitoring or follow-up would I need if I started treatment?

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources